Cargando…

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma

Natural killer T (NKT) cells represent a cell subpopulation that combines characteristics of natural killer (NK) cells and T cells. Through their endogenous T-cell receptors (TCRs), they reveal a pronounced intrinsic anti-tumor activity. Thus, a NKT cell transfected with a chimeric antigen receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon, Bianca, Wiesinger, Manuel, März, Johannes, Wistuba-Hamprecht, Kilian, Weide, Benjamin, Schuler-Thurner, Beatrice, Schuler, Gerold, Dörrie, Jan, Uslu, Ugur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121949/ https://www.ncbi.nlm.nih.gov/pubmed/30103488 http://dx.doi.org/10.3390/ijms19082365

Ejemplares similares

Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
por: Wiesinger, Manuel, et al.
Publicado: (2019)

Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update
por: Dörrie, Jan, et al.
Publicado: (2020)

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer
por: Simon, Bianca, et al.
Publicado: (2019)

RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma
por: Harrer, Dennis C., et al.
Publicado: (2017)

Blood Eosinophilia Is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA
por: Moreira, Alvaro, et al.
Publicado: (2020)

The future of affordable cancer immunotherapy
por: Schaft, Niels, et al.
Publicado: (2023)

A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma
por: Koch, Elias A. T., et al.
Publicado: (2022)

Immune Signatures and Survival of Patients With Metastatic Melanoma, Renal Cancer, and Breast Cancer
por: Wistuba-Hamprecht, Kilian, et al.
Publicado: (2020)

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
por: Harrer, Dennis C., et al.
Publicado: (2019)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells
por: Lutz, Manfred B, et al.
Publicado: (2014)

Preclinical evaluation of NF-κB-triggered dendritic cells expressing the viral oncogenic driver of Merkel cell carcinoma for therapeutic vaccination
por: Gerer, Kerstin F., et al.
Publicado: (2017)

Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells
por: Schuler-Thurner, Beatrice, et al.
Publicado: (2002)

Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders
por: Wiesinger, Manuel, et al.
Publicado: (2017)

A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells †
por: Bosch, Naomi C., et al.
Publicado: (2021)

Safety and tolerability of a single infusion of autologous ex vivo expanded regulatory T cells in adults with ulcerative colitis (ER-TREG 01): protocol of a phase 1, open-label, fast-track dose-escalation clinical trial
por: Voskens, Caroline J, et al.
Publicado: (2021)

Human Adenovirus-Specific γ/δ and CD8(+) T Cells Generated by T-Cell Receptor Transfection to Treat Adenovirus Infection after Allogeneic Stem Cell Transplantation
por: Dörrie, Jan, et al.
Publicado: (2014)

Natural killer cells for cancer immunotherapy: a new CAR is catching up
Publicado: (2019)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
por: Gaißler, Andrea, et al.
Publicado: (2023)

Just One Position-Independent Lysine Residue Can Direct MelanA into Proteasomal Degradation following N-Terminal Fusion of Ubiquitin
por: Setz, Christian, et al.
Publicado: (2013)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
por: Hoyer, Stefanie, et al.
Publicado: (2021)

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
por: Krückel, Annika, et al.
Publicado: (2019)

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
por: Schmidt, Dayane, et al.
Publicado: (2022)

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
por: Dörrie, Jan, et al.
Publicado: (2018)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Autologous regulatory T-cell transfer in refractory ulcerative colitis with concomitant primary sclerosing cholangitis
por: Voskens, Caroline, et al.
Publicado: (2023)

Extracellular vesicles from mature dendritic cells (DC) differentiate monocytes into immature DC
por: Schierer, Stefan, et al.
Publicado: (2018)

Conventional and three-dimensional photography as a tool to map distribution patterns of in-transit melanoma metastases on the lower extremity
por: Müller, Kilian, et al.
Publicado: (2023)

Immunomonitoring of Human Breast Milk Cells During HCMV-Reactivation
por: Lazar, Katrin, et al.
Publicado: (2021)

Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
por: Kirchberger, Michael Constantin, et al.
Publicado: (2018)

Blood Eosinophils Are Associated with Efficacy of Targeted Therapy in Patients with Advanced Melanoma
por: Wendlinger, Simone, et al.
Publicado: (2022)

Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
por: Schliep, Stefan, et al.
Publicado: (2018)

Age-associated alterations in γδ T-cells are present predominantly in individuals infected with Cytomegalovirus
por: Wistuba-Hamprecht, Kilian, et al.
Publicado: (2013)

Peripheral blood T-cell signatures from high-resolution immune phenotyping of γδ and αβ T-cells in younger and older subjects in the Berlin Aging Study II
por: Wistuba-Hamprecht, Kilian, et al.
Publicado: (2015)

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
por: Thurner, Beatrice, et al.
Publicado: (1999)

NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells
por: Bosch, Naomi C., et al.
Publicado: (2019)

Are natural killer cells superior CAR drivers?
por: Klingemann, Hans
Publicado: (2014)

Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade
por: Gaißler, Andrea, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_edlrp0rm0rgf66hojnujgkm0fa